Prognostic value of an immunohistochemical signature in patients with pulmonary squamous cell carcinoma undergoing complete surgical resection.
Pulmonary squamous cell carcinoma
immunohistochemical
predictor
prognostic
signature
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
07
01
2022
accepted:
16
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
ppublish
Résumé
The Tumor Node Metastasis (TNM) stage cannot accurately predict the prognosis of patients in pulmonary squamous cell carcinoma (SQCC). The aim of the present study was to evaluate the prognostic value of immunohistochemical (IHC)-based classifiers in patients with pulmonary SQCC who underwent complete surgery resection. From January 2010 to December 2014, a total of 556 patients with SQCC who underwent complete radical resection were included. The patients were grouped into a discovery group (n=334) and a validation group (n=222). Using the least absolute shrinkage and selection operator (LASSO) regression model, we extracted IHCs that were associated with progression-free survival (PFS) and then built classifiers. Clinicopathological variables and the IHC-based classifiers were analyzed using univariable and multivariable logistic regression analyses. A nomogram to predict PFS was constructed and validated using bootstrap resampling. Following the LASSO regression model, 4 IHC markers associated with PFS were identified. We used the IHC-based classifiers to stratify patients in both groups into high- and low-risk groups. PFS was better in the low-risk group than in the high-risk group in both the discovery and validation groups. Multivariate analysis demonstrated that the IHC-based classifiers were independently prognostic in predicting the PFS of patients with SQCC. The performance of the nomogram was evaluated and proven to be clinically useful. By combining IHC-based classification and clinicopathology, we were able to have better insight into the prognostic assessment of patients with SQCC after surgery, which can inform postoperative patient management.
Sections du résumé
Background
UNASSIGNED
The Tumor Node Metastasis (TNM) stage cannot accurately predict the prognosis of patients in pulmonary squamous cell carcinoma (SQCC). The aim of the present study was to evaluate the prognostic value of immunohistochemical (IHC)-based classifiers in patients with pulmonary SQCC who underwent complete surgery resection.
Methods
UNASSIGNED
From January 2010 to December 2014, a total of 556 patients with SQCC who underwent complete radical resection were included. The patients were grouped into a discovery group (n=334) and a validation group (n=222). Using the least absolute shrinkage and selection operator (LASSO) regression model, we extracted IHCs that were associated with progression-free survival (PFS) and then built classifiers. Clinicopathological variables and the IHC-based classifiers were analyzed using univariable and multivariable logistic regression analyses. A nomogram to predict PFS was constructed and validated using bootstrap resampling.
Results
UNASSIGNED
Following the LASSO regression model, 4 IHC markers associated with PFS were identified. We used the IHC-based classifiers to stratify patients in both groups into high- and low-risk groups. PFS was better in the low-risk group than in the high-risk group in both the discovery and validation groups. Multivariate analysis demonstrated that the IHC-based classifiers were independently prognostic in predicting the PFS of patients with SQCC. The performance of the nomogram was evaluated and proven to be clinically useful.
Conclusions
UNASSIGNED
By combining IHC-based classification and clinicopathology, we were able to have better insight into the prognostic assessment of patients with SQCC after surgery, which can inform postoperative patient management.
Identifiants
pubmed: 35280487
doi: 10.21037/jtd-22-118
pii: jtd-14-02-536
pmc: PMC8902106
doi:
Types de publication
Journal Article
Langues
eng
Pagination
536-545Informations de copyright
2022 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-118/coif). The authors have no conflicts of interest to declare.
Références
Cancer Cytopathol. 2019 May;127(5):325-339
pubmed: 31050216
Cancer Lett. 2002 Dec 1;186(1):115-20
pubmed: 12183083
J Thorac Dis. 2018 Nov;10(11):6107-6117
pubmed: 30622782
Asian Pac J Cancer Prev. 2015;16(5):1881-95
pubmed: 25773840
World J Gastroenterol. 2005 Aug 7;11(29):4587-91
pubmed: 16052694
Arch Biochem Biophys. 2019 Jan;661:97-106
pubmed: 30439360
Oncol Lett. 2020 Oct;20(4):49
pubmed: 32802169
Pathol Res Pract. 2001;197(3):157-64
pubmed: 11314778
Semin Cancer Biol. 2020 Dec;67(Pt 1):74-82
pubmed: 31412296
Arch Oral Biol. 2017 Oct;82:160-165
pubmed: 28645102
Ann Thorac Surg. 2012 Jun;93(6):1813-20; discussion 1820-1
pubmed: 22542070
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
J Thorac Oncol. 2017 Jul;12(7):1109-1121
pubmed: 28461257
Expert Rev Anticancer Ther. 2016 Jun;16(6):653-60
pubmed: 27010977
Stem Cells. 2013 Dec;31(12):2607-19
pubmed: 23940081
Clin Cancer Res. 1997 Oct;3(10):1879-87
pubmed: 9815577
Chest. 2003 Jun;123(6):2096-103
pubmed: 12796194
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Stem Cells. 2009 Jan;27(1):40-8
pubmed: 18948646
J Clin Oncol. 2016 Jun 20;34(18):2157-64
pubmed: 27138577
Int J Clin Exp Med. 2015 Apr 15;8(4):6406-11
pubmed: 26131266
Arch Pathol Lab Med. 2013 Sep;137(9):1191-8
pubmed: 23991729
Mod Pathol. 2012 Mar;25(3):405-15
pubmed: 22056955
Oncol Rep. 2020 Apr;43(4):1187-1198
pubmed: 32323802
Oncol Lett. 2016 Nov;12(5):3195-3198
pubmed: 27899982
Ai Zheng. 2003 Oct;22(10):1093-5
pubmed: 14558959
Int J Oncol. 2015 Feb;46(2):505-12
pubmed: 25384882
J Clin Oncol. 2013 Apr 20;31(12):1576-82
pubmed: 23509313
In Vivo. 2018 Mar-Apr;32(2):303-311
pubmed: 29475913
J Thorac Oncol. 2008 Aug;3(8):819-31
pubmed: 18670299
PLoS One. 2014 Apr 15;9(4):e95303
pubmed: 24736592
Anticancer Res. 2003 Nov-Dec;23(6D):5101-6
pubmed: 14981973